Rigel Pharmaceuticals, Inc.
| Nasdaq: RIGL
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel Pharmaceuticals focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include fostamatinib, an inhibitor for rheumatoid arthritis, R343, an inhibitor for asthma, R333 for the treatment of lupus of the skin and R348 for the treatment of keratoconjunctivitis sicca or chronic dry eye. Rigel Pharmaceuticals was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.